Development for the Peritoneal Carcinomatosis Index (PCI) in Ovarian Cancer
NCT ID: NCT01538498
Last Updated: 2013-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
134 participants
OBSERVATIONAL
2008-04-30
2013-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Secondary objectives: To establish the relationship and find out clinical significance between PCI, tumor location and tumor characteristics
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Pilot Test for Newly Developed Synoptic Operative Template for Ovarian Cancer (SOTOC): National Cancer Center - Peritoneal Carcinomatosis Index
NCT01823731
A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
NCT01570582
Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma
NCT06969833
Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer
NCT05827523
Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian Cancer
NCT05410015
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Informed consent
* Digital photography \& Checking PCI (tumor size, number, and Characteristics)
* Postoperative surveillance(tumor marker, image and physical examination)
1. Developing the best fitting PCI model to reflect recurrence-free survival and overall survival
* Selection of items
* Weighting by items and tumor characteristics
2. Analysis of prognostic impact of PCI compared to conventional staging system (FIGO stage) for ovarian cancer
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Available preoperative image study (CT and/or MRI and/or PET)
3. Patients who gave a written informed consent
4. Patients must be surgical candidate considering medical and psychological condition
Exclusion Criteria
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Center, Korea
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sang-Yoon Park
Chief, Center for Uterine Cancer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCCCTS-08-309
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.